Fennec Pharmaceuticals Q4 EPS $(0.10) Misses $(0.02) Estimate, Sales $9.73M Beat $8.67M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fennec Pharmaceuticals reported Q4 earnings with a loss of $(0.10) per share, missing the $(0.02) estimate by 400%, but showed a 61.54% improvement from last year. Sales reached $9.73M, exceeding the $8.67M estimate by 12.28% and marking a 534.20% increase from the previous year.
March 21, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Fennec Pharmaceuticals missed EPS estimates but significantly exceeded sales forecasts in Q4, showing strong year-over-year growth.
While the EPS miss might concern some investors, the substantial beat on sales forecasts and the impressive year-over-year growth in sales could offset negative sentiment. The mixed results present a neutral short-term outlook as investors weigh the significance of the earnings miss against the strong sales performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100